8-K: ENDRA Life Sciences Reshapes Executive Roles

ENDRA Life Sciences Inc. announced a strategic restructuring of its executive roles, with the Chief Technology Officer transitioning to a consulting role and the Chief Financial Officer's services being formalized through an advisory agreement.

Summary

• Michael Thornton resigned as Chief Technology Officer (CTO) of ENDRA Life Sciences Inc. effective November 28, 2025, and simultaneously entered into a Consulting Agreement with the company.
• Under the Consulting Agreement, Mr. Thornton will provide commercialization services, including test plan and system integration testing for the FLIP system software for pivotal clinical studies (GEN 2A) and De Novo request applications (GEN 2B), cybersecurity requirements, informatics, and intellectual property support.
• Mr. Thornton's compensation as a consultant will be $150 per hour for the first five hours per calendar week and $100 per hour for any hours exceeding five hours per calendar week, with an expectation of approximately ten hours per week.
• All of Mr. Thornton's outstanding Options and Restricted Stock Units will remain outstanding and continue to vest as long as he provides services under the Consulting Agreement.
• The company entered into an Advisory Services Agreement with Impact Solve, LLC (dba Impact Solutions), effective November 28, 2025, which supersedes a prior agreement, for the services of Richard Jacroux, the company's Chief Financial Officer.
• Richard Jacroux, through Impact Solutions, will serve as the company's Principal Financial Officer and Principal Accounting Officer.
• The initial base fee for Mr. Jacroux's services for 2025 is $8,650 per month, with an hourly rate of $124.70 for hours beyond 16 per week, representing a nearly 28% discount off standard fees.
• Effective January 1, 2026, the base fee for Mr. Jacroux's services will increase to $10,800 per month, and the hourly rate for hours beyond 16 per week will be $156.00, representing a 10% discount off standard fees, which will not increase through 2026.
• The discounted rates for Mr. Jacroux's services will remain in effect as long as Alexander Tokman is the Acting CEO or CEO; otherwise, standard fees will apply.

Sentiment

Score: 5

Explanation: The filing presents a neutral to slightly mixed sentiment. While retaining key talent in consulting roles is positive for continuity and specific project execution, the shift from employee to consultant for the CTO and the increased cost for CFO services introduce some operational and financial considerations. The focus on product development milestones (GEN 2A, GEN 2B) is favorable, but the reliance on external contractors for critical functions introduces some risks.

Positives

• The company retains the expertise of former CTO Michael Thornton for critical commercialization, product development, and regulatory activities related to the FLIP system (GEN 2A, GEN 2B, De Novo request, cybersecurity, IP support).
• Mr. Thornton's outstanding equity awards (Options and RSUs) will continue to vest, providing an incentive for his continued engagement and performance.
• The formalization of CFO Richard Jacroux's services through an Advisory Services Agreement provides clarity and continuity for key financial leadership roles.
• The specific deliverables outlined for Mr. Thornton's consulting role indicate a clear path for advancing the FLIP system towards clinical studies and market approval.

Negatives

• The transition of the Chief Technology Officer from an employee to an independent contractor role could signal a reduction in direct internal commitment or a shift in the company's long-term R&D strategy.
• The cost for the Chief Financial Officer's advisory services will increase significantly starting January 1, 2026, from $8,650 to $10,800 per month (base fee) and from $124.70 to $156.00 per hour for additional work.
• The company's reliance on external consultants for critical executive functions (CTO, CFO) may introduce challenges related to direct control, strategic integration, and long-term stability compared to full-time employee roles.

Risks

• Reliance on independent contractors for critical functions (CTO, CFO) may lead to less direct control and commitment compared to full-time employees, potentially impacting operational efficiency and strategic execution.
• The consulting and advisory agreements can be terminated with relatively short notice (15 days for Thornton, 30 days for Jacroux), posing a risk of disruption to key technical and financial operations.
• Michael Thornton's consulting agreement is non-exclusive, allowing him to provide similar services to other entities, potentially diluting his focus on ENDRA Life Sciences, though he is restricted from working for companies measuring liver fat.
• There is an explicit risk of potential misclassification of independent contractors, which could lead to tax, employment insurance, and workers' compensation liabilities for the company.
• The increased operational costs for financial services starting in 2026 could impact the company's financial performance if not offset by revenue growth or other cost efficiencies.

Future Outlook

The company's future outlook, as indicated by the consulting agreement, includes continued focus on advancing the FLIP system through pivotal clinical studies (GEN 2A) and securing regulatory approval via a De Novo request application (GEN 2B), alongside ongoing cybersecurity, intellectual property, and M&A support. The financial arrangements for the CFO are set through 2026, with an agreed-upon fee structure.

Industry Context

ENDRA Life Sciences operates in the medical device and diagnostic technology sector, specifically focusing on thermo & photo-acoustic technologies. The company's emphasis on 'pivotal clinical study release' and 'De Novo request marketing pathway classification' for its FLIP system is typical for medical technology firms in the advanced stages of product development and regulatory approval. The use of consulting and advisory agreements for key executive functions may reflect a strategy to manage costs, access specialized expertise flexibly, or adapt to the evolving needs of a company progressing towards commercialization, a common practice among smaller or growth-stage companies in the med-tech industry.

Management Changes

Corporate Governance

Related Party Transactions

• The Advisory Services Agreement with Impact Solve, LLC is a related party transaction, as Richard Jacroux, the company's Chief Financial Officer, is a principal of Impact Solve, LLC.

Stakeholder Impact

• Shareholders: Potential impact on operational costs due to increased CFO fees in 2026, continuity of key technical and financial expertise, and progress towards regulatory milestones for the FLIP system.
• Employees: Michael Thornton transitioned from an employee to an independent consultant, which may affect internal team dynamics and structure.
• Customers: Potential benefit from the continued development and regulatory progress of the FLIP system, which is supported by the consulting arrangements.
• Creditors: No direct impact on creditors is explicitly mentioned in the filing.

Next Steps

• Continued development and system integration testing of FLIP system software for a pivotal clinical study release (GEN 2A).
• Delivery of documentation and testing to fulfill Cyber-security requirements for a De Novo request marketing pathway classification for the FLIP system.
• Delivery of a test plan and system integration testing of FLIP system software for a De Novo request application (GEN 2B).
• Provision of informatics and intellectual property support to ensure an orderly transition of responsibility to ENDRA team members.
• Support of roadmap and integration, including product development, for potential partnerships and M&A activity.

Key Dates

Recommendation

The filing details planned management transitions and compensation structures, which are largely administrative and expected. While retaining key talent in consulting roles is positive for continuity, the shift to consulting for critical functions and the increased costs for financial services introduce some uncertainties. There are no immediate catalysts for significant upside or downside, suggesting a 'hold' position while monitoring the execution of product development milestones and the effectiveness of the new operational structure.

Keywords

ENDRA Life Sciences, NDRA, SEC filing, 8-K, Chief Technology Officer, CTO, Chief Financial Officer, CFO, consulting agreement, advisory services, corporate governance, management change, executive compensation, FLIP system, De Novo request, medical devices, diagnostic technology, thermo-acoustic, photo-acoustic, clinical study, GEN 2A, GEN 2B, cybersecurity, intellectual property